How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,516 results for

Alpha Adrenergic Antagonist

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. (PubMed)

A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Current medications for alcohol dependence (AD) show only modest efficacy. None target brain noradrenergic pathways. Theory and preclinical evidence suggest that noradrenergic circuits may be involved in alcohol reinforcement and relapse. We therefore tested the alpha-1 adrenergic receptor antagonist, prazosin, as a pharmacotherapy for AD.We randomized 24 participants with AD but without posttraumatic stress

Full Text available with Trip Pro

2009 Alcoholism, clinical and experimental research

122. alpha-1-Adrenergic Receptor Agonist Activity of Clinical alpha-Adrenergic Receptor Agonists Interferes with alpha-2-Mediated Analgesia. (PubMed)

alpha-1-Adrenergic Receptor Agonist Activity of Clinical alpha-Adrenergic Receptor Agonists Interferes with alpha-2-Mediated Analgesia. The use of alpha-2 adrenergic agonists for analgesia is limited due to a narrow therapeutic window. Definition of the role of alpha receptor subtypes in alpha agonist mediated analgesia may identify strategies to separate the analgesic from sedative and cardiovascular effects.Analgesic activity of brimonidine, clonidine, and tizanidine was investigated in wild (...) -selective antagonist 5-methylurapidil without affecting sedation. Following intraperitoneal administration, the therapeutic window was negligible for clonidine and tizanidine, but greater for brimonidine. 5-Methylurapidil enhanced the therapeutic window of intraperitoneal clonidine and tizanidine approximately 10-fold.Alpha-1A receptor agonist activity can counterbalance alpha-2 receptor agonist-induced analgesia. Greater alpha-2 selectivity may enhance the therapeutic window of alpha-2 agonists

Full Text available with Trip Pro

2009 Anesthesiology

123. Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

Diseases, Male Sexual Dysfunctions, Psychological Mental Disorders Tamsulosin Doxazosin Adrenergic Agents Adrenergic Antagonists Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urological Agents Antihypertensive Agents (...) Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2010 Clinical Trials

124. α1-Adrenergic receptor subtype function in fetal and adult cerebral arteries (PubMed)

α1-Adrenergic receptor subtype function in fetal and adult cerebral arteries In the developing fetus, cerebral artery (CA) contractility demonstrates significant functional differences from that of the adult. This may be a consequence of differential activities of alpha(1)-adrenergic receptor (alpha(1)-AR) subtypes. Thus we tested the hypothesis that maturational differences in adrenergic-mediated CA contractility are, in part, a consequence of differential expression and/or activities (...) of alpha(1)-AR subtypes. In CA from fetal ( approximately 140 days) and nonpregnant adult sheep, we used wire myography and imaging, with simultaneous measurement of tension and intracellular Ca(2+) concentration ([Ca(2+)](i)), radioimmunoassay, and Western immunoblots to examine phenylephrine (Phe)-induced contractile responses. The alpha(1A)-AR antagonists (5-MU and WB-4101) completely inhibited Phe-induced contraction in adult but not fetal CA; however, [Ca(2+)](i) increase was reduced significantly

Full Text available with Trip Pro

2010 American Journal of Physiology - Heart and Circulatory Physiology

125. Binding of amyloid β peptide to β2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity (PubMed)

Binding of amyloid β peptide to β2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity Progressive decrease in neuronal function is an established feature of Alzheimer's disease (AD). Previous studies have shown that amyloid beta (Abeta) peptide induces acute increase in spontaneous synaptic activity accompanied by neurotoxicity, and Abeta induces excitotoxic neuronal death by increasing calcium influx mediated by hyperactive alpha-amino-3-hydroxy-5-methyl-4-isoxazole (...) propionate (AMPA) receptors. An in vivo study has revealed subpopulations of hyperactive neurons near Abeta plaques in mutant amyloid precursor protein (APP)-transgenic animal model of Alzheimer's disease (AD) that can be normalized by an AMPA receptor antagonist. In the present study, we aim to determine whether soluble Abeta acutely induces hyperactivity of AMPA receptors by a mechanism involving beta(2) adrenergic receptor (beta(2)AR). We found that the soluble Abeta binds to beta(2)AR

Full Text available with Trip Pro

2010 The FASEB Journal

128. Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)

terms Hyperplasia Prostatic Hyperplasia Pathologic Processes Prostatic Diseases Genital Diseases, Male Silodosin Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urological Agents (...) Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH) Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2010 Clinical Trials

129. Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin

Dopamine Uptake Inhibitors Antihypertensive Agents Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Adrenergic Antagonists (...) and serotonin systems may be profoundly important in METH effects and dependence. However, these neurotransmitter systems have not been tested as extensively as targets of pharmacologic interventions. Thus, the purpose of this study is to examine whether the alpha-1-b antagonist prazosin blocks the self-reported effects, cognitive performance and cardiovascular effects of METH in a dose-related manner. Subsequent protocols will test the effect of the serotonin antagonist, cyproheptadine, and the combined

2010 Clinical Trials

130. The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries. (PubMed)

The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries. The goal was to identify alpha-1-adrenergic receptor (AR) subtypes in human coronary arteries.The alpha1-ARs regulate human coronary blood flow. The alpha1-ARs exist as 3 molecular subtypes, alpha1A, alpha1B, and alpha1D, and the alpha1D subtype mediates coronary vasoconstriction in the mouse. However, the alpha1A is thought to be the only subtype in human coronary arteries.We obtained (...) - and alpha1B-ARs mediate beneficial functional responses and coronary alpha1Ds mediate vasoconstriction. Thus, alpha1D-selective antagonists might mediate coronary vasodilation, without the negative cardiac effects of nonselective alpha1-AR antagonists in current use. Furthermore, it could be possible to selectively activate beneficial myocardial alpha1A- and/or alpha1B-AR signaling without causing coronary vasoconstriction.

Full Text available with Trip Pro

2009 Journal of the American College of Cardiology

132. Management of opioid use disorders: a national clinical practice guideline

. The recommendations in this guideline are based on the clin- ical evidence base regarding treatment approaches for opioid use disorder currently available in Canada, including oral opioid agonist treatment and antagonist pharmacotherapies, as well as withdrawal management strategies, residential treatment and psychosocial treatment interventions. The evidence base for pharmacotherapies not yet widely available in Canada, including long-acting and extended-release opioid antagonists, as well as injectable opioid (...) - tages of methadone and buprenorphine–naloxone are summarized in Table 2. Compared with use of a 2 -adrenergic agonists or psychosocial treatment alone, opioid agonist treatment with buprenorphine– naloxone or methadone has proven superior in terms of reten- tion in treatment, sustained abstinence from illicit opioid use, and reduced risk of morbidity and death. 21,25,37–40 Recent meta- analyses have found that buprenorphine–naloxone and metha- done were essentially equally efficacious across

2018 CPG Infobase

133. Management of stable angina

revascularisation Completely revised 5.8.3 Enhanced counterpulsation Completely revised 5.8.4 Other approaches New 6 Stable angina and non-cardiac surgery Completely revised 6.1 Assessment prior to surgery Minor update 6.2 Perioperative revascularisation Minor update 6.3 Drug therapy in patients undergoing non-cardiac surgery Completely revised 6.3.1 Beta blockers Completely revised 6.3.2 Alpha 2 adrenergic receptor agonists Completely revised 6.3.4 Antiplatelet therapy Completely revised 6.3.5 Statins (...) that, following an Independent Review Panel Assessment: ranolazine (Ranexa®) is not recommended for use within NHS Scotland. Indication under review: as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta blockers and/or calcium antagonists). The submitting company did not present a sufficiently robust clinical and economic case to gain acceptance by the Independent Review Panel

2018 SIGN

135. Effects of Alpha Blockers on Prostate-specific Antigen (PSA) Change in Men With Lower Urinary Tract Symptoms (LUTS)

with alpha-1 adrenergic antagonists, or AB was reported first in 1975, the therapeutic efficacy has been widely accepted and now AB medication is considered the first-line choice worldwide among pharmacologic options for BPH-related LUTS. Previous studies usually focused on the treatment efficacy or preventive role of AB for clinical progression of BPH and AB therapy in real-life practice improved BPH/LUTS and reduced the risk of overall clinical progression. However, the correlation between the change (...) Go to Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: PSA and alpha blockers First Posted: November 30, 2010 Last Update Posted: November 30, 2010 Last Verified: November 2010 Keywords provided by Seoul National University Hospital: prostate prostate-specific antigen benign prostatic hyperplasia adrenergic alpha-Antagonists Additional relevant MeSH terms: Layout table for MeSH terms Hyperplasia Prostatic Hyperplasia Lower Urinary Tract Symptoms

2010 Clinical Trials

136. LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers

for MeSH terms Erectile Dysfunction Sexual Dysfunction, Physiological Genital Diseases, Male Sexual Dysfunctions, Psychological Mental Disorders Vardenafil Dihydrochloride Adrenergic alpha-Antagonists Vasodilator Agents Phosphodiesterase 5 Inhibitors Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Urological Agents Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Physiological Effects of Drugs (...) LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2010 Clinical Trials

137. Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial

Posted: October 11, 2016 Last Verified: October 2016 Additional relevant MeSH terms: Layout table for MeSH terms Tamsulosin Adrenergic alpha-Antagonists Adrenergic alpha-1 Receptor Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urological Agents (...) Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2010 Clinical Trials

138. {alpha}2-Adrenoceptors Coordinate Swallowing and Respiration. (PubMed)

-adrenergic receptor agonist and enhanced by an alpha2-adrenergic receptor antagonist, indicating an important role of alpha2-adrenergic receptors in regulation of the coordination between swallowing and respiration in vitro. (...) {alpha}2-Adrenoceptors Coordinate Swallowing and Respiration. Because the discoordination between swallowing and respiration may cause severe respiratory disorders such as aspiration pneumonia, understanding the neuronal mechanisms underlying such coordination is important. Recently, it was reported that medullary noradrenergic neurons are involved in evoking esophageal-gastric relaxation reflex, leading to a hypothesis that such neurons are also involved in swallowing-respiration coordination

2010 Journal of Dental Research

139. Adaptations of the Autonomous Nervous System Controlling Heart Rate Are Impaired by a Mutant Thyroid Hormone Receptor-{alpha}1. (PubMed)

aimed to analyze the role of TRalpha1 signaling in the autonomic control of heart rate using an implantable radio telemetry system. We identified that mice expressing the mutant TRalpha1R384C (TRalpha1+m mice) displayed a mild bradycardia, which becomes more pronounced during night activity or on stress and is accompanied by a reduced expression of nucleotide-gated potassium channel 2 mRNA in the heart. Pharmacological blockage with scopolamine and the beta-adrenergic receptor antagonist timolol (...) Adaptations of the Autonomous Nervous System Controlling Heart Rate Are Impaired by a Mutant Thyroid Hormone Receptor-{alpha}1. Thyroid hormone has profound direct effects on cardiac function, but the hormonal interactions with the autonomic control of heart rate are unclear. Because thyroid hormone receptor (TR)-alpha1 has been implicated in the autonomic control of brown adipose energy metabolism, it might also play an important role in the central autonomic control of heart rate. Thus, we

Full Text available with Trip Pro

2010 Endocrinology

140. Guidelines on Diagnosis and Management of Syncope

1914 5.2.5.2 Alpha-agonists 1914 5.2.5.3 Beta-blockers 1915 5.2.5.4 Other drugs 1915 5.2.5.5 Emerging new therapies in specific subgroups 1915 5.2.6 Cardiac pacing 1915 5.2.6.1 Evidence from trials in suspected or certain reflex syncope and electrocardiogram- documented asystole 1915 5.2.6.2 Evidence from trials in patients with carotid sinus syndrome 1915 5.2.6.3 Evidence from trials in patients with tilt-induced vasovagal syncope 1916 5.2.6.4 Evidence from trials in patients with adenosine

Full Text available with Trip Pro

2018 European Society of Cardiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>